A Phase 3 clinical trial has found that the combination of Gilead’s antibody-drug conjugate Trodelvy with Merck’s immunotherapy Keytruda significantly reduced the risk of disease progression or death in patients with an aggressive form of breast cancer.
Source: https://endpts.com/trodelvy-and-keytruda-combo-succeeds-in-phase-3-breast-cancer-study